View this email as a web page

Sponsored Message:

Developed under the direction and sponsorship of Bristol-Myers Squibb Company

‌

Immunomodulatory agents' mechanism
helped multiple myeloma come a long way1,2

Research is exploring maximizing mechanistic performance through CELMoD1,3

‌

CELMoD=cereblon E3 ligase modulation

Immunomodulatory agents’ ability to kill cancer cells and stimulate the immune system is limited by the potential of their mechanism.1,3-7*†

Research continues into CELMoD to harness the potential of this mechanism in multiple myeloma.1

Based on in vitro studies examining the mechanism of immunomodulatory agents as well as studies using human multiple myeloma cell lines that investigated the effects of immunomodulatory agents on multiple myeloma cell killing and the immune system1,3-7

‌†

Current immunomodulatory agents have an ~20% rate of inducing the closed/active state of cereblon based on in vitro data1,3,8,9

Discover the potential with CELMoD research

References: 1. Liu Y, Mo CC, Hartley-Brown MA, et al. Expert Rev Hematol. 20‌24;1‌7(‌8):4‌4‌5-4‌6‌5. do‌i:1‌0.1‌08‌0/‌1‌74‌74‌08‌6.2‌02‌4.‌23‌82‌89‌7 2. Costacurta M, He J, Thompson PE, Shortt J. J Pers Med. 20‌21‌;1‌1(‌11‌):11‌85.‌ do‌i:‌10‌.33‌90‌/jpm‌11‌11‌11‌85‌ 3. Watson ER, Novick S, Matyskiela ME, et al. Science. 20‌22‌;37‌8(‌661‌9):‌54‌9-5‌53‌. do‌i:1‌0.1‌126‌/sc‌ien‌ce.‌add‌757‌4 4. Davies FE, Raje N, Hideshima T, et al. Blood . 2‌00‌1;9‌8(1‌):2‌10-‌21‌6. do‌i:1‌0.1‌18‌2/b‌lo‌od.‌v9‌8.1‌.2‌1‌0 5. Hideshima T, Chauhan D, Shima Y, et al. Blood. 2‌0‌00;‌96(9‌):2‌94‌3-29‌50. 6. Görgün G, Calabrese E, Soydan E, et al. Blood. 2‌01‌0;1‌16(‌1‌7):3‌22‌7-3‌23‌7. do‌i:1‌0.1‌18‌2/b‌lo‌od-2‌01‌0-0‌4-27‌98‌93 7. Hayashi T, Hideshima T, Akiyama M, et al. Br J Haematol. 20‌05;‌12‌8(2‌):1‌92‌-2‌03. do‌i:10‌.1‌11‌1/‌j.13‌65-2‌14‌1.20‌04.‌05‌286‌ 8. Mo Z, Groocock L, Wood S, et al. Blood Cancer Discov. 2026;7(1):104-128. doi:10.1158/2643-3230.BCD-25-0059 9. Mo Z, Groocock L, Wood S, et al. Supplementary information. Blood Cancer Discov. 2026;7(1):104-128. doi:10.1158/2643-3230.BCD-25-0059

This promotional email was sent by Bristol Myers Squibb, and is intended for U.S. Healthcare providers only.

Legal Notice

H‌E-U‌S-26‌00‌27‌2 0‌3/2‌6

By unsubscribing from this email you are not opting out of email marketing communication from Bristol‑Myers Squibb.

This content is sponsored by Bristol-Myers Squibb, and ION Oncology Practice Network has not independently reviewed or verified the information provided by Bristol-Myers Squibb.

This email was sent to karleigh.bard-marsh@cencora.com because you have an account with or are a valued partner of Cencora Specialty GPOs | ION Oncology Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.